Study of PsA (N = 341) pts starting secukinumab with or without a baseline loading dose of SEC 150 mg, showed equal ACR20 responses at week 16 - 41.2% vs 39.8%. Despite some w/ an earlier response, the SEC loading dose may not be necessary. https://t.co/d3z9AQoeGM